- Home
- PLBC vs ABEO Comparison
PLBC vs ABEO Comparison
Compare PLBC & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLBC | ABEO |
|---|---|---|
| Founded | 1980 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.2M | 399.5M |
| IPO Year | 2002 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PLBC | ABEO |
|---|---|---|
| Price | $62.48 | $5.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $57.67 | $20.00 |
| AVG Volume (30 Days) | 44.1K | ★ 1.6M |
| Earning Date | 04-15-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ 2.79 | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | $25.59 | $1,024.31 |
| Revenue Next Year | $5.15 | $145.42 |
| P/E Ratio | $22.61 | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $39.89 | $4.00 |
| 52 Week High | $64.00 | $7.65 |
Technical Indicators
Market Signals| Indicator | PLBC | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 63.96 | 37.94 |
| Support Level | $60.50 | $5.67 |
| Resistance Level | $63.74 | $6.07 |
| Average True Range (ATR) | 1.05 | 0.33 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 68.86 | 7.95 |
Price Performance
Historical ComparisonAbout PLBC Plumas Bancorp
Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.